EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Efficacy of Dihydroartemisinin–Piperaquine for Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Timika, Papua, Indonesia

Noy Norman Kambuaya, Muhammad Syawal Satria Ramli, Freis Candrawati, Enny Kenangalem, Pak Prayoga, Agatha Mia Puspitasari, Rintis Noviyanti, Leily Trianty, Ratni Indrawanti, Minerva Simatupang, Reynold R Ubra, Jenny Hill und 2 weitere

The American Journal of Tropical Medicine and Hygiene · 2026

DOI: 10.4269/ajtmh.25-0291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2026. Verfasst von Noy Norman Kambuaya und 13 weiteren Autor:innen. Beteiligte Einrichtung: Timika Research Facility, Papuan Health and Community Development Foundation, Timika, Indonesia. Hauptthemen laut MEDLINE: Malaria, Vivax, Artemisinins, Quinolines, Antimalarials. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydroartemisinin–piperaquine (DP), the first-line treatment for uncomplicated malaria in Timika, Papua, Indonesia, has also been used for intermittent preventive treatment in pregnancy (IPTp-DP) since February 2022. Concerns about the potential emergence of drug resistance associated with this dual policy prompted the present study, which was conducted to assess DP efficacy in treating uncomplicated Plasmodium falciparum ( P. falciparum ) and Plasmodium vivax ( P. vivax ) malaria in the general population 15 months after IPTp-DP was introduced. Between May and December 2023, the current study recruited 75 P. falciparum and 75 P. vivax malaria patients, who received supervised DP treatment for 3 days. Clinical and laboratory data were collected daily (on days 1, 2, 3, and 7) and then weekly for 6 weeks. Molecular analysis was performed to detect genetic markers of P. falciparum resistance to DP and distinguish between recrudescence and reinfection. A total of 68 P. falciparum and 58 P. vivax patients completed their day 42 follow-up. The cumulative risk of same-species recurrence by day 42 was 1.5% (95% CI: 0–7.9%) in P. falciparum patients (polymerase chain reaction-adjusted) and 5.2% (95% CI: 1.1–14.1%) for P. vivax patients (unadjusted). No patients exhibited parasitemia on day 3. No P. falciparum isolates carried kelch 13 gene mutations or exhibited increased plasmepsin 2–3 copy numbers on either day 0 (0/75) or at recurrence (0/2). At the current level of IPTp-DP coverage (824 doses administered), there was no evidence of high treatment failure rates or the selection of resistant parasites in patients with uncomplicated malaria treated with DP. Continuous monitoring of DP efficacy remains crucial for both treatment and chemoprevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, VivaxArtemisininsQuinolinesAntimalarialsMalaria, FalciparumHumansIndonesiaFemaleAdultPlasmodium vivaxPlasmodium falciparumMaleYoung AdultAdolescentTreatment OutcomeDrug ResistanceMiddle AgedChildDrug Therapy, CombinationPregnancyPiperazines

Substanzen

piperaquineartenimolArtemisininsQuinolinesAntimalarialsPiperazines

Autor:innen und Institutionen

  • Timika Research Facility, Papuan Health and Community Development Foundation, Timika, Indonesia.
  • Exeins Health Initiative, Jakarta, Indonesia.
  • Eijkman Research Center for Molecular Biology-BRIN, Jakarta, Indonesia.
  • Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
  • Indonesian Ministry of Health, Jakarta, Indonesia.
  • Mimika District Health Office, Timika, Indonesia.

Zitieren

APA

Kambuaya, N. N., Ramli, M. S. S., Candrawati, F., Kenangalem, E., Prayoga, P., Puspitasari, A. M., Noviyanti, R., Trianty, L., Indrawanti, R., Simatupang, M., Ubra, R. R., Hill, J., Hafidz, F., & Poespoprodjo, J. R. (2026). Treatment Efficacy of Dihydroartemisinin–Piperaquine for Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Timika, Papua, Indonesia. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.25-0291

Vancouver

Kambuaya NN, Ramli MSS, Candrawati F, Kenangalem E, Prayoga P, Puspitasari AM, et al. Treatment Efficacy of Dihydroartemisinin–Piperaquine for Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Timika, Papua, Indonesia. The American Journal of Tropical Medicine and Hygiene. 2026. doi:10.4269/ajtmh.25-0291

BibTeX
@article{Kambuaya2026,
  author = {Kambuaya, Noy Norman and Ramli, Muhammad Syawal Satria and Candrawati, Freis and Kenangalem, Enny and Prayoga, Pak and Puspitasari, Agatha Mia and Noviyanti, Rintis and Trianty, Leily and Indrawanti, Ratni and Simatupang, Minerva and Ubra, Reynold R and Hill, Jenny and Hafidz, Firdaus and Poespoprodjo, Jeanne Rini},
  title = {Treatment Efficacy of Dihydroartemisinin–Piperaquine for Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Timika, Papua, Indonesia},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2026},
  doi = {10.4269/ajtmh.25-0291}
}
Kostenlos starten →